Saha D - Search Results

1

Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.

Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Saha D, et al. J Med Chem. 2021 Aug 26;64(16):11747-11773. doi: 10.1021/acs.jmedchem.0c02167. Epub 2021 Aug 17. J Med Chem. 2021. PMID: 34402300 Free PMC article. Review.

2

The Exploration of Chirality for Improved Druggability within the Human Kinome.

Saha D, Kharbanda A, Yan W, Lakkaniga NR, Frett B, Li HY. Saha D, et al. J Med Chem. 2020 Jan 23;63(2):441-469. doi: 10.1021/acs.jmedchem.9b00640. Epub 2019 Oct 9. J Med Chem. 2020. PMID: 31550151 Free PMC article. Review.

3

Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach.

Saha D, Ryan KR, Lakkaniga NR, Smith EL, Frett B. Saha D, et al. ChemMedChem. 2021 May 18;16(10):1605-1608. doi: 10.1002/cmdc.202100013. Epub 2021 Mar 8. ChemMedChem. 2021. PMID: 33559353 Free PMC article.

4

Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors.

Kharbanda A, Zhang L, Saha D, Tran P, Xu K, Li MO, Leung YK, Frett B, Li HY. Kharbanda A, et al. Among authors: saha d. Eur J Med Chem. 2021 Nov 5;223:113660. doi: 10.1016/j.ejmech.2021.113660. Epub 2021 Jun 19. Eur J Med Chem. 2021. PMID: 34246853 Free PMC article.

5

Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group.

Swafford K, Acharya B, Xu YZ, Raney T, McCrury M, Saha D, Frett B, Kendrick S. Swafford K, et al. Among authors: saha d. Genes (Basel). 2022 Jun 25;13(7):1144. doi: 10.3390/genes13071144. Genes (Basel). 2022. PMID: 35885931 Free PMC article.

6

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.

Acharya B, Saha D, Armstrong D, Lakkaniga NR, Frett B. Acharya B, et al. Among authors: saha d. RSC Med Chem. 2022 May 23;13(7):798-816. doi: 10.1039/d2md00067a. eCollection 2022 Jul 20. RSC Med Chem. 2022. PMID: 35923716 Free PMC article. Review.

7

Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma.

McCrury M, Swafford K, Shuttleworth SL, Mehdi SH, Acharya B, Saha D, Naceanceno K, Byrum SD, Storey AJ, Xu YZ, Doshier C, Patel V, Post GR, De Loose A, Rodriguez A, Shultz LD, Zhan F, Yoon D, Frett B, Kendrick S. McCrury M, et al. Among authors: saha d. Mol Cancer Ther. 2024 Mar 4;23(3):316-329. doi: 10.1158/1535-7163.MCT-23-0299. Mol Cancer Ther. 2024. PMID: 37816504

8

Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia.

Frett B, Stephens KE, Koss B, Melnyk S, Farrar J, Saha D, Roy Choudhury S. Frett B, et al. Among authors: saha d. Cancer Sci. 2024 Mar;115(3):963-973. doi: 10.1111/cas.16069. Epub 2024 Jan 16. Cancer Sci. 2024. PMID: 38226414 Free PMC article.

9

Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules.

Acharya B, Saha D, Armstrong D, Jabali B, Hanafi M, Herrera-Rueda A, Lakkaniga NR, Frett B. Acharya B, et al. Among authors: saha d. RSC Med Chem. 2023 Dec 12;15(2):399-415. doi: 10.1039/d3md00457k. eCollection 2024 Feb 21. RSC Med Chem. 2023. PMID: 38389874 Review.

10

Imaging Methods for the Assessment of a Complex Hydrogel as an Ocular Drug Delivery System for Glaucoma Treatment: Opportunities and Challenges in Preclinical Evaluation.

Das S, Saha D, Majumdar S, Giri L. Das S, et al. Among authors: saha d. Mol Pharm. 2022 Mar 7;19(3):733-748. doi: 10.1021/acs.molpharmaceut.1c00831. Epub 2022 Feb 18. Mol Pharm. 2022. PMID: 35179892 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

842 results

Search Page